🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

195 results for “Boehringer” Clear

  1. A study in people with overweight or obesity to test how BI 1820237, BI 456906, or a combination of both affects brain activity

    Boehringer Ingelheim

    Obesity

    phase 1 other active

    1 trial

  2. A study to compare how different medicines (rosuvastatin, digoxin, metformin, and furosemide) are handled by the body of healthy people and people with liver cirrhosis

    Boehringer Ingelheim

    1. Patients with compensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh A 2. Patients with decompensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh B

    phase 1 other active

    1 trial

  3. A study to compare how different substances (caffeine, warfarin, omeprazole, metoprolol, and midazolam) are handled by the body of healthy people and people with liver cirrhosis

    Boehringer Ingelheim

    1. Patients with compensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh A 2. Patients with decompensated liver cirrhosis due to any underlying liver disease with advanced fibrosis (F4) and hepatic impairment that meets the criteria for Child-Pugh B

    phase 1 other active

    1 trial

  4. A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapy

    Boehringer Ingelheim

    Metastatic pancreatic ductal adenocarcinoma (mPDAC)

    phase 1 other active

    1 trial

  5. A study to test BI 765179 alone and in combination with ezabenlimab in patients with advanced cancer (solid tumors) and BI 765179 in combination with pembrolizumab in patients with advanced head and neck cancer

    Boehringer Ingelheim

    Advanced head and neck cancer

    phase 1 other active

    1 trial

  6. A study to test different doses of BI 1823911 alone and combined with other medicines in people with different types of advanced cancer with KRAS mutation.

    Boehringer Ingelheim

    solid tumour harbouring G12C mutation

    phase 1 other active

    1 trial

  7. A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors).

    Boehringer Ingelheim

    solid tumors

    phase 1 other active

    1 trial

  8. A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors)

    Boehringer Ingelheim

    advanced, unresectable and/or metastatic solid tumors

    phase 1 other active

    1 trial

  9. A study to test different doses of BI 765049 in people with advanced cancer of the colon, rectum, stomach, or pancreas

    Boehringer Ingelheim

    colorectal carcinoma (CRC)

    phase 1 other active

    1 trial

  10. A study to test different doses of obrixtamig (BI 764532) in patients with small cell lung cancer and other neuroendocrine tumours that are positive for DLL3.

    Boehringer Ingelheim

    Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3

    phase 1 other active

    1 trial

  11. A study to test how BI 3031185 is tolerated by people with borderline personality disorder or attention-deficit/hyperactivity disorder.

    Boehringer Ingelheim

    Attention deficit hyperactivity disorder, Borderline personality disorder

    phase 1 other active

    1 trial

  12. A study to test how BI 456906 is taken up in the blood of people with and without kidney problems

    Boehringer Ingelheim

    Renal impairment (mild, moderate and severe), Healthy

    phase 1 other active

    1 trial

  13. A study to test how different doses of BI 1703880 in combination with ezabenlimab are tolerated in people with different types of advanced cancer (solid tumours)

    Boehringer Ingelheim

    Advanced solid tumours

    phase 1 other active

    1 trial

  14. A study to test how different doses of BI 3731579 are tolerated by healthy people

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  15. A study to test how different doses of BI 3814916 are tolerated by healthy people

    Boehringer Ingelheim

    healthy volunteer trial

    phase 1 other active

    1 trial

  16. A study to test how well different doses of BI 3031185 are tolerated by healthy men and women

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  17. A study to test how well different doses of BI 3034701 are tolerated by healthy men and people with overweight or obesity

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  18. A study to test how well different doses of BI 3804379 are tolerated by healthy people and patients with MASH

    Boehringer Ingelheim

    Metabolic Dysfunction-associated Steatohepatitis

    phase 1 other active

    1 trial

  19. A study to test how well different doses of BI 3810477 are tolerated by healthy men

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  20. A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)

    Boehringer Ingelheim

    Advanced relapsed or refractory ovarian cancer, Advanced relapsed or refractory endometrial cancer, Advanced relapsed or refractory germ cell tumours

    phase 1 other active

    1 trial

  21. A study to test how well different doses of BI 764532 are tolerated by people with a tumour in the brain that is positive for DLL3

    Boehringer Ingelheim

    Glioma expressing DLL3

    phase 1 other active

    1 trial

  22. A study to test how well healthy people tolerate spesolimab when given in 2 different ways.

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  23. A study to test how well multiple doses of BI 3810477 are tolerated by healthy adults.

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

  24. A study to test how well multiple doses of BI 765423 are tolerated by healthy men

    Boehringer Ingelheim

    Healthy volunteer trial

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources